PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung

With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression...

Full description

Bibliographic Details
Main Authors: Janzic Urska, Kern Izidor, Janzic Andrej, Cavka Luka, Cufer Tanja
Format: Article
Language:English
Published: Sciendo 2017-09-01
Series:Radiology and Oncology
Subjects:
Online Access:https://doi.org/10.1515/raon-2017-0037
id doaj-9104b551aa43462e8b685d9eeb1a62eb
record_format Article
spelling doaj-9104b551aa43462e8b685d9eeb1a62eb2021-09-05T14:00:10ZengSciendoRadiology and Oncology1581-32072017-09-0151335736210.1515/raon-2017-0037raon-2017-0037PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lungJanzic Urska0Kern Izidor1Janzic Andrej2Cavka Luka3Cufer Tanja4Department of Medical Oncology, University Clinic Golnik, Golnik, SloveniaDepartment of Pathology, University Clinic Golnik, Golnik, SloveniaUniversity of Ljubljana, Faculty of Pharmacy, Ljubljana, SloveniaDepartment of Medical Oncology, Institute of Oncology, Ljubljana, SloveniaDepartment of Medical Oncology, University Clinic Golnik, Golnik, SloveniaWith introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients.https://doi.org/10.1515/raon-2017-0037lung cancersquamous-cell lung canceradenocarcinomatumor cellsimmune cellspd-l1 expression
collection DOAJ
language English
format Article
sources DOAJ
author Janzic Urska
Kern Izidor
Janzic Andrej
Cavka Luka
Cufer Tanja
spellingShingle Janzic Urska
Kern Izidor
Janzic Andrej
Cavka Luka
Cufer Tanja
PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
Radiology and Oncology
lung cancer
squamous-cell lung cancer
adenocarcinoma
tumor cells
immune cells
pd-l1 expression
author_facet Janzic Urska
Kern Izidor
Janzic Andrej
Cavka Luka
Cufer Tanja
author_sort Janzic Urska
title PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
title_short PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
title_full PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
title_fullStr PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
title_full_unstemmed PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
title_sort pd-l1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
publisher Sciendo
series Radiology and Oncology
issn 1581-3207
publishDate 2017-09-01
description With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients.
topic lung cancer
squamous-cell lung cancer
adenocarcinoma
tumor cells
immune cells
pd-l1 expression
url https://doi.org/10.1515/raon-2017-0037
work_keys_str_mv AT janzicurska pdl1expressioninsquamouscellcarcinomaandadenocarcinomaofthelung
AT kernizidor pdl1expressioninsquamouscellcarcinomaandadenocarcinomaofthelung
AT janzicandrej pdl1expressioninsquamouscellcarcinomaandadenocarcinomaofthelung
AT cavkaluka pdl1expressioninsquamouscellcarcinomaandadenocarcinomaofthelung
AT cufertanja pdl1expressioninsquamouscellcarcinomaandadenocarcinomaofthelung
_version_ 1717812364190941184